The strong anti-cancer effect of ID4 previously reported in prostate cancer and cross-talk with p53 will provide a strong framework of study in other systems, which eventually could serve as an attractive therapeutic approach [50]. This evidence concerns the gene TP53 and prostate carcinoma.